Morgan Stanley Issues Pessimistic Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price target cut by equities researchers at Morgan Stanley from $183.00 to $166.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the specialty pharmaceutical company's stock. Morgan Stanley's target price suggests a potential upside of 53.85% from the company's previous close.

Several other research analysts have also commented on the company. Barclays restated an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $185.79.

Jazz Pharmaceuticals Trading Down 8.7 %

JAZZ opened at $107.90 on Wednesday. The business has a 50 day moving average of $121.47 and a 200-day moving average of $122.47. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $6.65 billion, a PE ratio of 14.79, a PEG ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same quarter in the previous year, the business earned $2.68 EPS. The company's revenue for the quarter was down .5% on a year-over-year basis. Equities research analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares in the company, valued at $1,189,587.54. The trade was a 36.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,236 shares of company stock worth $3,956,190 in the last three months. 4.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in JAZZ. LSV Asset Management grew its position in shares of Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after acquiring an additional 37,108 shares during the last quarter. Pacer Advisors Inc. grew its position in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after purchasing an additional 115,102 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares during the last quarter. Capital World Investors grew its holdings in shares of Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after buying an additional 104,195 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after acquiring an additional 315,608 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.